FOXO4-DRI is a synthetic D-retro-inverso peptide derived from the FOXO4 transcription factor interaction surface with the tumor suppressor protein p53. It is classified as a protein-protein interaction interfering peptide designed to disrupt the FOXO4-p53 binding interface within senescent cells.
Through competitive disruption of nuclear FOXO4-p53 binding, FOXO4-DRI releases p53 from a survival-promoting interaction that normally maintains senescent cells in a viable, secretory state. This release permits p53-dependent apoptotic signaling to proceed selectively in senescent cells, while proliferating and quiescent cells remain largely unaffected. The D-retro-inverso configuration provides enhanced proteolytic stability while preserving the side-chain topology required for target engagement.
FOXO4-DRI is actively investigated across several research domains, including cellular-senescence biology, longevity research, chemotherapy-induced cellular-stress research models, and tissue-aging investigations. Published studies have demonstrated that FOXO4-DRI selectively induces apoptosis in senescent cells in vitro and restores fitness, fur density, and renal function parameters in naturally aged and accelerated-aging mouse models (Baar et al., 2017, Cell). Its mechanistic specificity has established FOXO4-DRI as a reference senolytic research tool.
The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.
See also: Epitalon, NAD⁺, and SS-31 10 mg.
Specifications
- Purity: 99%
- Quantity: 10 mg
- Molecular Formula: Not publicly disclosed
- Molecular Weight: ~4–5 kDa (approximate)
Reviews
There are no reviews yet.